|
$9-10 target, trading under $3 right now.
http://www.thestreet.com/_yahoo/story/10... http://www.thestreet.com/_yahoo/story/10... Chelsea is hoping for better results from the second of two pivotal studies of droxidopa in patients with orthostatic hypotension, a condition in which blood pressure drops when a patient stands up, causing dizziness and other symptoms. The initial phase III study failed in September, although the drug did show some beneficial activity. Rating :
 (No ratings) |
 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.05